EL7.AI
StocksMedium•6 November 2026•
2 min read

Health Catalyst Revenue Reaches $56.28 Million in Third Quarter Despite 26.3% Decline

Key Facts

1Revenue was $56.28 million in the third quarter of 2026, beating analysts’ consensus of $55.44 million by 1.5%.
2Adjusted loss per share was $0.03, compared with an expected loss of $0.05, a difference of $0.02 per share.
3HCAT shares closed at $1.50 on 5 November 2026.
4Third-quarter 2025 revenue was $76.323 million, with gross margin of 39% and net loss of $22.229 million.

Health Catalyst reported revenue of $56.28 million in the third quarter of 2026, down 26.3% year over year, according to data cited by StockStory. Revenue came in above analysts’ consensus estimate of $55.44 million, beating it by 1.5%. The figures showed a contrast between exceeding near-term expectations and continued contraction compared with the third quarter of 2025. In that quarter, the company reported revenue of $76.323 million, according to its official results. The annual decline puts the limited quarterly revenue growth above expectations in the context of a lower sales base than a year earlier.

Adjusted loss per share was $0.03, compared with an expected loss of $0.05, according to StockStory. The actual loss was therefore $0.02 per share below the consensus estimate. But the improvement over expectations does not change that the company reported an adjusted loss per share during the quarter. In the year-earlier comparison, net loss was $22.229 million in the third quarter of 2025. Gross margin then reached 39%, according to the company’s official earnings release.

The company had previously set third-quarter guidance for revenue of between $55 million and $56 million, and Adjusted EBITDA of between zero and $0.5 million. It later said both revenue and Adjusted EBITDA exceeded the upper ends of their announced ranges. That means actual revenue also topped the ceiling of previous guidance, not just analysts’ estimate. In the second quarter of 2026, Health Catalyst reported revenue of $70.487 million, down 13% year over year. Adjusted EBITDA in that quarter was $9.919 million, up 6% year over year.

The company’s shares, listed under the ticker HCAT, closed at $1.50 on 5 November 2026, according to EL7 data. The close came on the day the third-quarter results were announced, while documented data did not include the session’s trading range. The results highlight a mix of revenue above expectations and an adjusted loss per share narrower than analysts had estimated, alongside an annual revenue decline. Revenue in the year-earlier period was higher than in the current quarter, and the company also recorded a net loss then. These comparisons provide a picture of reported performance and market expectations for the quarter, without removing the continuing annual decline in revenue.

Open on chart